Cargando…

Delamanid suppresses CXCL10 expression via regulation of JAK/STAT1 signaling and correlates with reduced inflammation in tuberculosis patients

BACKGROUND: Apart from bactericidal effects, anti-tuberculosis drugs can interfere with the host’s immune system. In this study, we analyzed the role of delamanid (DLM), an inhibitor of mycolic acid synthesis of mycobacterial cell wall, on human macrophages. METHODS: Based on a cohort of multidrug-r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiao, Min, Li, Shanshan, Yuan, Jinfeng, Ren, Weicong, Shang, Yuanyuan, Wang, Wei, Liu, Rongmei, Zhang, Fuzhen, Li, Qing, Wu, Xiao, Lu, Jie, Gao, Mengqiu, Pang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679411/ https://www.ncbi.nlm.nih.gov/pubmed/36426362 http://dx.doi.org/10.3389/fimmu.2022.923492

Ejemplares similares

Integrated bioinformatics analysis of dendritic cells hub genes reveal potential early tuberculosis diagnostic markers
por: Wu, Xiao, et al.
Publicado: (2023)

Predominance of Escherichia-Shigella in Gut Microbiome and Its Potential Correlation with Elevated Level of Plasma Tumor Necrosis Factor Alpha in Patients with Tuberculous Meningitis
por: Li, Shanshan, et al.
Publicado: (2022)

Significant difference in Th1/Th2 paradigm induced by tuberculosis-specific antigens between IGRA-positive and IGRA-negative patients
por: Li, Qiang, et al.
Publicado: (2022)

The role of delamanid in the treatment of drug-resistant tuberculosis
por: Lewis, Joseph M, et al.
Publicado: (2015)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

Attenuated Cytokine-Induced Memory-Like Natural Killer Cell Responses to Mycobacterium tuberculosis in Tuberculosis Patients
por: Liang, Chen, et al.
Publicado: (2023)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Rarity of rpoB Mutations Outside the Rifampicin Resistance-Determining Region of Mycobacterium tuberculosis Isolates from Patients Responding Poorly to First-Line Tuberculosis Regimens in Beijing, China: A Retrospective Study
por: Guo, Jidong, et al.
Publicado: (2021)

Development and clinical evaluation of a CRISPR/Cas13a-based diagnostic test to detect Mycobacterium tuberculosis in clinical specimens
por: Ren, Weicong, et al.
Publicado: (2023)

Delamanid: A new armor in combating drug-resistant tuberculosis
por: Xavier, Alphienes Stanley, et al.
Publicado: (2014)

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
por: Skripconoka, Vija, et al.
Publicado: (2013)

Delamanid expanded access novel treatment of drug resistant tuberculosis
por: Rustomjee, Roxana, et al.
Publicado: (2015)

Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
por: Marwah, Vikas, et al.
Publicado: (2023)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Dependence of Xpert MTB/RIF Accuracy for Detecting Rifampin Resistance in Bronchoalveolar Lavage Fluid on Bacterial Load: A Retrospective Study in Beijing, China
por: Qin, Lin, et al.
Publicado: (2021)

Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis
por: Liu, Kewei, et al.
Publicado: (2022)

Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells
por: Fenwick, Peter S., et al.
Publicado: (2015)

Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]
Publicado: (2016)

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Wang, Xiaofeng, et al.
Publicado: (2020)

C9ORF72 suppresses JAK-STAT mediated inflammation
por: Pang, Weilun, et al.
Publicado: (2023)

Increased Expression of IL-10 in Peripheral Blood Mononuclear Cells Correlates with Negative Interferon-γ Release Assay Results in Culture-Confirmed Tuberculosis Patients
por: Guo, Jidong, et al.
Publicado: (2021)

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
por: Zhu, Hanzhao, et al.
Publicado: (2023)

Diagnostic Yield of Oral Swab Testing by TB-LAMP for Diagnosis of Pulmonary Tuberculosis
por: Song, Yanhua, et al.
Publicado: (2021)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa
por: Mohr, Erika, et al.
Publicado: (2018)

Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients
por: Reichmuth, Martina L., et al.
Publicado: (2020)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Formulation and Scale-up of Delamanid Nanoparticles via Emulsification for Oral Tuberculosis Treatment
por: Caggiano, Nicholas J., et al.
Publicado: (2023)

The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant Mycobacterium tuberculosis Strains
por: Lyu, Xia-Li, et al.
Publicado: (2021)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

CXCL6 Promotes Renal Interstitial Fibrosis in Diabetic Nephropathy by Activating JAK/STAT3 Signaling Pathway
por: Sun, Meng-Yao, et al.
Publicado: (2019)

Serum Cytokine Biomarkers for Use in Diagnosing Pulmonary Tuberculosis versus Chronic Pulmonary Aspergillosis
por: Ren, Weicong, et al.
Publicado: (2023)

Dipyrithione inhibits IFN-γ-induced JAK/STAT1 signaling pathway activation and IP-10/CXCL10 expression in RAW264.7 cells
por: Han, Cui, et al.
Publicado: (2010)

Study on the Correlation between Interleukin-27 and CXCL10 in Pulmonary Tuberculosis
por: Fan, Jiahui, et al.
Publicado: (2022)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis
por: Sasaki, Tomohiro, et al.
Publicado: (2022)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9120rknri9kvlb3mirdbm8gng8